In attendance:

**QIBA PET Amyloid Biomarker Committee**
12 February 2016 at 9 AM CT
Call Summary

<table>
<thead>
<tr>
<th>In attendance:</th>
<th>RSNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Perlman, MD (co-chair)</td>
<td>Adriaan Lammertsma, PhD</td>
</tr>
<tr>
<td>Christopher Buckley, PhD</td>
<td>Martin Lodge, PhD</td>
</tr>
<tr>
<td>Santiago (Santi) Bullich, PhD</td>
<td>Dawn Matthews, MS, MBA</td>
</tr>
<tr>
<td>Paul Kinahan, PhD</td>
<td>Nancy Obuchowski, PhD</td>
</tr>
<tr>
<td>Gregory Klein, PhD</td>
<td>Sara Sheikbahaei, PhD</td>
</tr>
</tbody>
</table>

**Literature Analysis / Claim Language (Drs. Obuchowski / Subramaniam)**

- A study using fluorine-18-labeled amyloid imaging agents including 23 Alzheimer’s disease patients was reviewed
- **Guidelines for assigning values for claim statements** were discussed
- Items in progress:
  - Confidence intervals with plausible values for the repeatability coefficient
  - Determine scanning component error re SUV measurements; establishing SUV thresholds needed
  - Clinical requirements as related to clinical needs for quantitative imaging biomarker performance

**Phantom / DRO Update (Drs. Sunderland / Kinahan)**

- The phantom is being used to solve a scanning error by segmenting out the imaging aspect for detailed analysis
- Goal is to achieve a grey to white matter contrast that is appropriate for amyloid tracers, avoiding void volumes
- The team is starting with negative cases where white matter and the brain stem are used
- It was noted that it is vitally important that tracer manufacturers provide input
  - Details will be used to update the Profile more extensively
- Items still needed are:
  - POREX specs on pore volume percent in order to get pricing quotes for both positive and negative values
  - Which structure should be used for grey and white matter target contrast

**Profile Revisions (Ms. Matthews)**

- A well-organized flow chart will be included in section 3.4.3, which will be a user-friendly feature
- The team will be asked to review the document again prior to release for public comment
- Reviewers are also asked to use “track changes” in Word – Dr. Perlman will collate all edits and clearly highlight recent changes made for reviewer convenience

---

**Nuclear Medicine BC Calls:**

- Feb 19: SPECT BC
- Feb 26: Combined NM BCs - TBD

**SPECT Task Forces: (Tuesdays at 2 pm CT)**

- Feb 16: Phantoms / DRO Group – Drs. Dickson and Zimmerman
- Feb 23: Clinical / Literature Review – Dr. Seibyl

---